Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Factors contributing to the adverse drug reactions associated with the dipeptidyl peptidase-4 (DPP-4) inhibitors: A scoping review
Authors
Keywords
-
Journal
Diabetes & Metabolic Syndrome-Clinical Research & Reviews
Volume 17, Issue 7, Pages 102790
Publisher
Elsevier BV
Online
2023-06-03
DOI
10.1016/j.dsx.2023.102790
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Analysis of Severe Hypoglycemia Among Adults With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
- (2022) Ji-Yeon Lee et al. JAMA Network Open
- Incretin-Based Drugs and the Risk of Acute Liver Injury Among Patients With Type 2 Diabetes
- (2022) Richeek Pradhan et al. DIABETES CARE
- Pharmacovigilance study of the association between dipeptidyl peptidase–4 inhibitors and angioedema using the FDA Adverse Event Reporting System (FAERS)
- (2022) Katsuhiro Ohyama et al. Scientific Reports
- Safety and effectiveness of linagliptin in Korean patients with type 2 diabetes mellitus: A post‐marketing surveillance study
- (2021) Jaehyun Bae et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors may accelerate cirrhosis decompensation in patients with diabetes and liver cirrhosis: a nationwide population-based cohort study in Taiwan
- (2021) Fu-Shun Yen et al. Hepatology International
- Sex differences associated with adverse drug reactions resulting in hospital admissions
- (2021) L. C. Hendriksen et al. Biology of Sex Differences
- Angioedema associated with dipeptidyl peptidase-IV inhibitors
- (2021) Nicoletta Cassano et al. Clinical and Molecular Allergy
- Long-Term Safety and Efficacy of Teneligliptin in Elderly Patients with Type 2 Diabetes: Subgroup Analysis of a 3-Year Post-Marketing Surveillance in Japan
- (2020) Takashi Kadowaki et al. ADVANCES IN THERAPY
- Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan
- (2020) Yosuke Ishida et al. Expert Opinion On Drug Safety
- Evaluation of efficacy and safety of DPP-4 inhibitors for Chinese elderly patients with type 2 diabetes mellitus
- (2020) Dong-Ni Yu et al. Diabetology & Metabolic Syndrome
- Angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibitor–induced angioedema: A disproportionality analysis of the WHO pharmacovigilance database
- (2020) Marion Lepelley et al. Journal of Allergy and Clinical Immunology-In Practice
- Adverse Drug Reactions in Patients with CKD
- (2020) Solène M. Laville et al. Clinical Journal of the American Society of Nephrology
- Adverse Drug Effects in Patients with CKD
- (2020) Mark A. Perazella et al. Clinical Journal of the American Society of Nephrology
- Dipeptidyl peptidase‐4 inhibitor treatment and the risk of bullous pemphigoid and skin‐related adverse events: A systematic review and meta‐analysis of randomized controlled trials
- (2020) Wenjia Yang et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Sex differences in pharmacokinetics predict adverse drug reactions in women
- (2020) Irving Zucker et al. Biology of Sex Differences
- Gender differences in adverse event reports associated with antidiabetic drugs
- (2020) Kyung-In Joung et al. Scientific Reports
- Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
- (2019) Giorgio Sesti et al. ACTA DIABETOLOGICA
- Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes
- (2019) Seon Gu Lee et al. JAMA Dermatology
- Angioedema following initiation of Glecaprevir/ Pibrentasvir while on Sitagliptin
- (2019) Amanda Schneider et al. Journal of Allergy and Clinical Immunology-In Practice
- Use of dipeptidyl peptidase‐4 inhibitors and the risk of arthralgia: Population‐based cohort and nested case–control studies
- (2019) Chen‐Yu Wang et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
- (2019) Sieta T. Vries et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
- (2019) Fumiko Yamamoto et al. Diabetes Therapy
- Long-Term, Real-World Safety and Efficacy of Teneligliptin: A Post-Marketing Surveillance of More Than 10,000 Patients with Type 2 Diabetes in Japan
- (2019) Takashi Kadowaki et al. ADVANCES IN THERAPY
- Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
- (2018) Timothy M. E. Davis et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of long-term treatment with teneligliptin: Interim analysis of a post-marketing surveillance of more than 10,000 Japanese patients with type 2 diabetes mellitus
- (2018) Takashi Kadowaki et al. EXPERT OPINION ON PHARMACOTHERAPY
- Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study
- (2018) Outi Varpuluoma et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
- (2018) Masakazu Haneda et al. Diabetes Therapy
- Safety and Efficacy of Teneligliptin in Patients with Type 2 Diabetes Mellitus and Impaired Renal Function: Interim Report from Post-marketing Surveillance
- (2018) Masakazu Haneda et al. Diabetes Therapy
- PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
- (2018) Andrea C. Tricco et al. ANNALS OF INTERNAL MEDICINE
- Prevalence Estimates for Pemphigoid in the United States: a gender and age adjusted population analysis
- (2018) Sara Wertenteil et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden
- (2017) Lennart Holm et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Adverse safety events in patients with Chronic Kidney Disease (CKD)
- (2016) Ada Offurum et al. Expert Opinion On Drug Safety
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
- (2016) Ling Li et al. BMJ-British Medical Journal
- Adverse events associated with incretin-based drugs in Japanese spontaneous reports: a mixed effects logistic regression model
- (2016) Daichi Narushima et al. PeerJ
- Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin
- (2016) Jong Ho Kim et al. Diabetes & Metabolism Journal
- Effect of Vildagliptin on Hepatic Steatosis
- (2015) Mavin Macauley et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury
- (2015) Masahiro Asakawa et al. SpringerPlus
- Effects of Polypharmacy on Adverse Drug Reactions among Geriatric Outpatients at a Tertiary Care Hospital in Karachi: A Prospective Cohort Study
- (2014) Bilal Ahmed et al. PLoS One
- Decreased Gastric Motility in Type II Diabetic Patients
- (2014) Yi-Chun Chiu et al. Biomed Research International
- Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
- (2014) Masato Odawara et al. Diabetes Therapy
- Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?
- (2013) Y. Saisho et al. DIABETIC MEDICINE
- Risk Factors for Adverse Symptoms During Dipeptidyl Peptidase-IV Inhibitor Therapy: A Questionnaire-Based Study Carried Out by the Japan Pharmaceutical Association Drug Event Monitoring Project in Kumamoto Prefecture
- (2013) Ayami Kajiwara et al. DRUG SAFETY
- Female gender as a susceptibility factor for drug-induced liver injury
- (2013) David E Amacher HUMAN & EXPERIMENTAL TOXICOLOGY
- The development of angioedema in a patient with type 2 diabetes due to a novel dipeptidyl peptidase-IV inhibitor, anagliptin
- (2013) Hidetaka Hamasaki et al. INTERNATIONAL JOURNAL OF CARDIOLOGY
- Safety and efficacy of teneligliptin: a novel DPP-4 inhibitor for hemodialysis patients with type 2 diabetes
- (2013) Hideo Otsuki et al. INTERNATIONAL UROLOGY AND NEPHROLOGY
- Factors affecting the development of adverse drug reactions (Review article)
- (2013) Muaed Jamal Alomar SAUDI PHARMACEUTICAL JOURNAL
- Safety and efficacy of linagliptin in type 2 diabetes patients with common renal and cardiovascular risk factors
- (2013) Baptist Gallwitz Therapeutic Advances in Endocrinology and Metabolism
- Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors
- (2012) Larry K. Golightly et al. CLINICAL PHARMACOKINETICS
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Sitagliptin-Associated Angioedema
- (2012) A. R. Gosmanov et al. DIABETES CARE
- Incidence and Mortality of Bullous Pemphigoid in France
- (2012) Pascal Joly et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
- (2011) A.J. Scheen DIABETES & METABOLISM
- A Case of Drug-induced Hepatic Injury Associated with Sitagliptin
- (2011) Megumi Toyoda-Akui et al. INTERNAL MEDICINE
- Angio-oedema induced by dual dipeptidyl peptidase inhibitor and angiotensin II receptor blocker: a first case report
- (2010) S. Skalli et al. DIABETIC MEDICINE
- Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study
- (2010) Adrian Reuben et al. HEPATOLOGY
- Incretin-Based Therapies: Viewpoints on the way to consensus
- (2009) Michael. A. Nauck et al. DIABETES CARE
- Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema
- (2009) Nancy J. Brown et al. HYPERTENSION
- Hypoglycaemia in Type 2 diabetes
- (2008) S. A. Amiel et al. DIABETIC MEDICINE
- Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis
- (2008) Debora Williams-Herman et al. BMC Endocrine Disorders
- The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers
- (2007) Yan-Ling He et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started